April 2021

Editorial Board
Published in issue: April 2021
i

International Liver Congress™ 2021 - Showcase & celebrate your research!
Published in issue: April 2021
ii-iii

Join the EASL Community & enjoy reduced fees to all EASL events
Published in issue: April 2021
iv

Visit EASL Campus & discover 4,100 + resources on hepatology & liver-related research
Published in issue: April 2021
v

Contents
Published in issue: April 2021
vii-ix

From the Editor's Desk

From the Editor’s Desk...
• Patrizia Burra,
• Frank Tacke,
• Vlad Ratziu,
• Stefan Zeuzem,
• Bruno Sangro,
• Paolo Angeli
Published in issue: April 2021
p765-768

JHEP at a Glance

JHEP at a glance (April 2021)
Published in issue: April 2021
e49-e63

Editorials

Clinical utility of polygenic risk scores for predicting NAFLD disorders
• Alain Dessein
Published online: February 27, 2021
p769-770

Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche
• Luca Fabris,
• Massimiliano Cadamuro,
• Laura Fouassier
Published online: February 11, 2021
p771-774

Research Articles

NAFLD and Alcohol-Related Liver Diseases


Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
• Cristiana Bianco,
• Oveis Jamialahmadi,
• Serena Pelusi,
• ...
• Daniele Prati,
• Stefano Romeo,
• Luca Valenti
Published online: November 25, 2020
p775-782
Open Access

Viral Hepatitis


Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B
• Greta Acerbi,
• Ilaria Montali,
• Gennaro Domenico Ferrigno,
• ...
• Daniele Del Rio,
• Carlo Ferrari,
• Paola Fisicaro
Published online: November 11, 2020
p783-793
Open Access

Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity
• Aleksei Suslov,
• Marie-Anne Meier,
• Sylvia Ketterer,
• Xueya Wang,
• Stefan Wieland,
• Markus Hermann Heim
Published online: November 11, 2020
p794-800
Open Access

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
• Julia Dietz,
• Velia Chiara Di Maio,
• Adolfo de Salazar,
• ...
• HCV Virology Italian Resistance Network (VIRONET-C) collaborators,
• Spanish GEHEP-004 Collaborators,
• Members of the German HCV resistance study group
Published online: November 18, 2020
p801-810

Cirrhosis and Liver Failure


Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis
• José Ferrusquía-Acosta,
• Octavi Bassegoda,
• Laura Turco,
• ...
• Filippo Schepis,
• Marco Senzolo,
• Virginia Hernández-Gea
Published online: October 14, 2020
p811-818

Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality
• Dalila Costa,
• Benedikt Simbrunner,
• Mathias Jachs,
• ...
• Michael Trauner,
• Mattias Mandorfer,
• Thomas Reiberger
Published online: October 16, 2020
p819-828
Open Access

Hepatic and Biliary Cancer


A novel waitlist dropout score for hepatocellular carcinoma – identifying a threshold that predicts worse post-transplant survival
• Neil Mehta,
• Jennifer L. Dodge,
• John P. Roberts,
• Francis Y. Yao
Published online: November 11, 2020
p829-837

Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma
• Yu-Hua Huang,
• Chris Zhi-yi Zhang,
• Qun-Sheng Huang,
• ...
• Stephanie Ma,
• Mu-Sheng Zeng,
• Jing-Ping Yun
Published online: November 16, 2020
p838-849
Open Access

Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B
• Feng Su,
• Noel S. Weiss,
• Lauren A. Beste,
• ...
• Pamela Green,
• Kristin Berry,
• George N. Ioannou
Published online: November 24, 2020
p850-859

TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression
• Benjamin J. Dwyer,
• Edward J. Jarman,
• Jully Gogoi-Tiwari,
• ...
• Grant A. Ramm,
• Janina E.E. Tirnitz-Parker,
• Stuart J. Forbes
Published online: November 19, 2020
p860-872
Open Access

Liver Transplantation


Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients
• Bashar Aqel,
• Karn Wijarnpreecha,
• Surakit Pungpapong,
• ...
• Michael Leise,
• Lanyu Mi,
• Rolland C. Dickson
Published online: November 11, 2020
p873-880

Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction
• Vatche G. Agopian,
• Daniela Markovic,
• Goran B. Klintmalm,
• ...
• Hasan Yersiz,
• Douglas G. Farmer,
• Ronald W. Busuttil
Published online: September 22, 2020
p881-892

Experimental and Translational Hepatology


ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma
• Maria Arechederra,
• Sehrish K. Bazai,
• Ahmed Abdouni,
• ...
• Daniela S. Allende,
• Suneel S. Apte,
• Flavio Maina
Published online: November 13, 2020
p893-906

Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma
• Chunxiao Liu,
• Zhengyu Zha,
• Chenhao Zhou,
• ...
• Shao-Chun Wang,
• Ning Ren,
• Mien-Chie Hung
Published online: October 04, 2020
p907-918

IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression
• Stephanie Stein,
• Lara Henze,
• Tobias Poch,
• ...
• Johannes Herkel,
• Dorothee Schwinge,
• Christoph Schramm
Published online: November 13, 2020
p919-930
Open Access

Review

Systemic treatment of HCC in special populations
• Lorenza Rimassa,
• Nicola Personeni,
• Carolin Czauderna,
• Friedrich Foerster,
• Peter Galle
Published online: November 25, 2020
p931-943

Special Sections

Position Paper

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
• Markus Cornberg,
• Maria Buti,
• Christiane S. Eberhardt,
• Paolo Antonio Grossi,
• Daniel Shouval
Published online: February 06, 2021
p944-951

Thematic Miniseries on HCV cure


Residual risk of liver disease after hepatitis C virus eradication
• Francesco Negro
Published online: December 01, 2020
p952-963

Hepatology Snapshot


Remaining challenges in HCV elimination
• Camelia Capraru,
• Jordan J. Feld
Published online: February 12, 2021
p964-965

Letters to the Editor

SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination
• Javier Crespo,
• Álvaro Díaz-González,
• Paula Iruzubieta,
• Susana Llerena,
• Joaquín Cabezas
Published online: October 08, 2020
p966-967
Hepatic benefits of HCV cure: Don't forget coagulation!
• Alberto Zanetto,
• Paolo Simioni,
• Francesco Paolo Russo
Published online: December 16, 2020
p967-968
Reply to: “Hepatic benefits of HCV cure: Don't forget coagulation!”
• Vincenza Calvaruso,
• Antonio Craxì
Published online: December 16, 2020
p969
The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD
• Meixi Liu,
• Lejia Sun,
• Yilei Mao
Published online: December 16, 2020
p970-971
Reply to: “The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD”
• Javier Ampuero,
• Rocío Gallego-Durán,
• Manuel Romero-Gómez
Published online: December 23, 2020
p971-972
Non-alcoholic fatty liver disease: Not time for an obituary just yet!
• Shivaram Prasad Singh,
• Prajna Anirvan,
• K. Rajender Reddy,
• ...
• Subrat Kumar Acharya,
• Anuradha Supun Dassanayake,
• Khean-Lee Goh
Published online: December 16, 2020
p972-974

Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling
• Mingfeng Xia,
• Hailuan Zeng,
• Sijia Wang,
• Huiru Tang,
• Xin Gao
Published online: December 16, 2020
p974-977
Yet more evidence that MAFLD is more than a name change
• Mohammed Eslam,
• Vlad Ratziu,
• Jacob George
Published online: January 13, 2021
p977-979
“Dual aetiology fatty liver disease”: A recently proposed term associated with potential pitfalls
• Christophe Moreno,
• Nick Sheron,
• Dina Tiniakos,
• Carolin Lackner,
• Philippe Mathurin
• on behalf of EASL Consortium for the Study of Alcohol-related LiVer disease in Europe (SALVE)
Published online: December 16, 2020
p979-982
A new definition for non-alcoholic fatty liver disease
• Jaime Poniachik,
• Juan Pablo Roblero,
• Alvaro Urzúa,
• Maximo Cattaneo
Published online: December 16, 2020
p982-983
MAFLD: A holistic view to redefining fatty liver disease
• Mohammed Eslam,
• Jacob George
Published online: January 12, 2021
p983-985
Correspondence on “Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers”
• Nadia Russolillo,
• Luca Aldrighetti,
• Alfredo Guglielmi,
• Felice Giuliante,
• Alessandro Ferrero
Published online: December 16, 2020
p985-986
Reply to: “Letter regarding Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers”
• Christian Hobeika,
• David Fuks
Published online: January 21, 2021
p987-988
Is the name ‘NAFLD’ too big to fail? Let’s keep it for ‘nutrition-associated fatty liver disease’
• Gyorgy Baffy
Published online: December 16, 2020
p988
Clinical utility of the MAFLD definition
• Kenneth I. Zheng,
• Dan-Qin Sun,
• Yi Jin,
• Pei-Wu Zhu,
• Ming-Hua Zheng
Published online: December 17, 2020
p989-991
NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change
• Robert Hegarty,
• Sobha Singh,
• Sanjay Bansal,
• Emer Fitzpatrick,
• Anil Dhawan
Published online: January 22, 2021
p991-992
MAFLD: A game changer redefining fatty liver disease for adults and children
• Mohammed Eslam,
• Jacob George
Published online: January 13, 2021
p992-994

External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs
• Gamal Shiha,
• Nabiel Mikhail,
• Reham Soliman
Published online: December 16, 2020
p994-996
Reply to: “External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs”
• Rong Fan,
• Xueru Yin,
• Jinlin Hou
Published online: January 12, 2021
p996-997

Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
• Martin Depaire,
• Hélène Larrue,
• Marika Rudler,
• Jean Charles Nault,
• Christophe Bureau
Published online: December 16, 2020
p997-999
Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease
• Prasanta Debnath,
• Pravin Rathi
Published online: December 16, 2020
p999-1000
Reply to: “Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease”
• Dalila Costa,
• Benedikt Simbrunner,
• Thomas Reiberger
Published online: January 23, 2021
p1000-1001